Chemical Supply Chains Will Undergo A Major Transformation Post Covid-19
The coronavirus
pandemic has exacerbated an unprecedented shift in the choices of the
industrialists after a significant halt in the supply chains across the
Northern hemisphere. Battered by the lack of reliability and transparency
issues, economies are rerouting their supply chains after China became the
origin of the threatening pandemic that the world is trying to get rid of.
Although, China has become quite successful in defeating the contagion after
struggling for almost three months, analysts assume that the outbreak high
lightened the need of the hour for the world to contract their reliance for the
essential raw materials and Active Pharmaceutical Intermediates to a specific
region and protect it from other vulnerabilities. With its severe impact on
global supply chains, the major economies which had been making good money
through trade flows, are now only left with containers stranded in the wrong
locations as there is an indefinite delay in the overseas shipments.
Visit more info: https://www.chemanalyst.com/NewsAndDeals/NewsHome
Impact on
Indian Supply Chains
·
Growth in Longer Term
The European
Fine Chemicals Group, an association of API manufacturers in Europe EFCG
estimates that more than 80% of chemicals used to make drugs sold in Europe are
sourced from China and India. The group has been keeping a close eye such a
heavy reliance for these essential raw materials since 2017, when an
environmental crackdown by the Chinese government led to a wave of plant
closures. Loss of China as a reliable source of raw materials which holds
almost 25 per cent share would mean a greater share of India in the market,
which currently stands at 3 per cent. Better research and development
initiatives in chemistry and engineering will fetch India competitive advantage
in the years to come. However, it solely depends on the country’s chemical
players how they tap this value-creating opportunity and function to shape the
future of the industry in India to push country’s trade performance.
Post the
outbreak, the Indian government is under a constant thought about fostering
pharmaceutical infrastructure developments, granting environmental clearance,
and providing tax exemptions and subsidies to support the local manufacturing
of drugs. Government of India has decided to promote domestic production of key
Starting Materials (KSMs) or Intermediates and Active Pharmaceutical
Ingredients (APIs) in the country. The government is out with a scheme which will
promote Bulk Drug Parks and involve the financial investment of INR 3,000 crore in the next five years.
·
Supply chain vulnerabilities
The disruptions
in supply chains existed much before the imposition of the lockdowns as the
spread of Covid-19 across the world gave a major blow to the trade flows as
soon as the virus originated in the Wuhan province of China. India relies
heavily on China for raw materials. Certain Indian industries like pharmaceuticals
(China satisfies almost 70 per cent of country’s active pharmaceutical
ingredients (API) demand ), automobiles (China exports about 10-30 per cent of
the raw materials and base components to India), chemicals and textiles are
heavily dependent on China. This overdependency has become a serious issue for
national health security, prompting the Indian government to set up a special taskforce
to review the internal API sector as it senses possible shortages of volumes in
the Indian market further leading to problems like skyrocketing import prices.
Get the
Chemical and Petrochemical Industry News on Daily Basis,
Weekly-Trend
& Forecast and Monthly-Analyst Views
Subscribe Today!
News on WhatsApp/WeChat/Mail
First 15 days free news!
WhatsApp
No. +91-9914868686
For sales related query,
dial +91-9958299626 or +91-8882336899 or email at sales@chemanalyst.com
Source: ChemAnalyst
Comments
Post a Comment